Biocon to launch new branded formulations: Report

Biocon is all set to launch new branded formulations of its own and introduce products licensed from others to treat diabetes and cancer in the coming months. In this regards, the company will also approach more doctors through field staff and use digital technologies to train doctors and bring awareness among patients.

Moreover, the company is in talks with prospective partners for in-licensing novel molecules to strengthen its portfolio. Further, the company is planning to launch two key biosimilars bevacizumab and adalimumab in India in the near future.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.